Platelet-rich plasma therapy as a first-line treatment for severe Achilles tendon tear: a case report

2011 ◽  
Vol 18 (2) ◽  
pp. 101-105 ◽  
Author(s):  
Steven Sampson ◽  
Danielle Aufiero ◽  
Michael Meng ◽  
Anthony Bledin ◽  
Terry Gillette ◽  
...  
Keyword(s):  
Case Report ◽  
Achilles Tendon ◽  
Platelet Rich Plasma ◽  
Line Treatment ◽  
First Line ◽  
Tendon Tear ◽  
Plasma Therapy ◽  
First Line Treatment

Refractory eosinophilic fasciitis successfully treated with infliximab: A case report

2021 ◽  
pp. 239719832110043
Author(s):  
Paulina Śmigielska ◽  
Justyna Czarny ◽  
Jacek Kowalski ◽  
Aleksandra Wilkowska ◽  
Roman J. Nowicki
Keyword(s):  
Case Report ◽  
Connective Tissue ◽  
Treatment Failure ◽  
Immunosuppressive Drugs ◽  
Unknown Etiology ◽  
High Dose ◽  
Eosinophilic Fasciitis ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report

2020 ◽  
Vol 176 (5) ◽  
pp. 402-404
Author(s):  
K. El Husseini ◽  
F. Marguet ◽  
A. Lamy ◽  
N. Magne ◽  
M. Fontanilles
Keyword(s):  
Case Report ◽  
Line Treatment ◽  
Newly Diagnosed ◽  
First Line ◽  
Major Response ◽  
First Line Treatment

California rocket fuel: And what about being a first line treatment?

2016 ◽  
Vol 33 (S1) ◽  
pp. S551-S551
Author(s):  
J. Silva ◽  
J. Mota ◽  
P. Azevedo
Keyword(s):  
Case Report ◽  
Depressive Symptoms ◽  
Case Reports ◽  
Drug Resistant ◽  
Line Treatment ◽  
First Line ◽  
Depressed Woman ◽  
Rocket Fuel ◽  
Resistant Depression ◽  
First Line Treatment

IntroductionThe association venlafaxine-mirtazapine is currently known as California Rocket Fuel (CRF). Studies show advantage in terms of efficacy and rapid control of depressive symptoms compared to other associations. Venlafaxine is a selective serotonin-noradrenalin reuptake inhibitor and mirtazapine is a noradrenergic-specific serotonergic antidepressant: the result is a potent noradrenergic and serotonergic effect. Studies say that CRF should be performed only for drug-resistant depression; however, there are case reports of its use as a first line treatment, in selected patients.ObjectivesTo summarize the latest literature about this field and to present a case report.AimTo explore and critically review the controversies of venlafaxine-mirtazapine association as a first line antidepressants strategy.MethodsA brief review of the latest literature was performed, using PubMed and the keywords “venlafaxine-mirtazapine association”. A case report about a depressed woman is presented.ResultsDespite most studies are referent to its utility in drug-resistant depression, there are recent pilot studies that recommend CRF as a first line option.M., a 64-year-old woman, had her first psychiatric consultation. She had been depressed for 2 years, she lost 10 kg, had total insomnia and suicidal thoughts. CRF was started up to 150/15 mg, daily. An improvement was noticed after two weeks of treatment and the stabilization of depressive symptoms were achieved by the fourth month.ConclusionsCRF seems to be effective and useful. Patients with insomnia and weight loss may benefit from CRF as a first line option. However, more studies are needed.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease

2016 ◽  
Vol 13 (5) ◽  
pp. e528-e530 ◽  
Author(s):  
Yaping Wang ◽  
Minghong Bi ◽  
Haoran Zhang ◽  
Zhenyuan Gao ◽  
Hairong Zhou ◽  
...  
Keyword(s):  
Case Report ◽  
Gastric Carcinoma ◽  
Partial Response ◽  
Advanced Disease ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Poster 215 Platelet-Rich Plasma Therapy for Chronic Distal Biceps Tendon Tear: A Case Report

PM&R ◽  
2014 ◽  
Vol 6 (9) ◽  
pp. S260-S261
Author(s):  
Michael J. Ingraham ◽  
Arthur J. Deluigi ◽  
Bryan Murtaugh
Keyword(s):  
Case Report ◽  
Platelet Rich Plasma ◽  
Biceps Tendon ◽  
Distal Biceps Tendon ◽  
Tendon Tear ◽  
Plasma Therapy ◽  
Distal Biceps

Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash

2020 ◽  
Vol 26 (8) ◽  
pp. 2028-2030
Author(s):  
Ben E Anderson ◽  
Tiana S Luczak ◽  
Lauren M Ries ◽  
Gena E Hoefs ◽  
Anne C Silva-Benedict
Keyword(s):  
Case Report ◽  
Treatment Option ◽  
Anaplastic Lymphoma Kinase ◽  
Gene Rearrangement ◽  
Kinase Inhibitor ◽  
Skin Toxicity ◽  
Line Treatment ◽  
First Line ◽  
Anaplastic Lymphoma ◽  
First Line Treatment

Introduction Alectinib is an oral tyrosine kinase inhibitor currently recommended by the National Comprehensive Cancer Network (NCCN) as the preferred first-line treatment option for the treatment of metastatic anaplastic lymphoma kinase (ALK) gene rearrangement-positive non-small cell lung cancer (NSCLC). Skin toxicity is a known adverse effect of this medication, yet current recommendations are unclear regarding how to best manage patients who develop severe skin toxicity while taking alectinib. Case report Here, we describe a case of successful rechallenge with alectinib by utilizing a desensitization procedure in a patient who had developed severe alectinib-induced skin toxicity about two weeks into treatment. Management and outcome: Upon resolution of the initial skin toxicity symptoms, the patient was rechallenged with alectinib using a modified version of a previously published desensitization procedure. The patient tolerated the rechallenge with no recurrence of skin toxicity or other adverse effects and was able to continue treatment with alectinib. Discussion Alectinib is currently recommended as the preferred first-line treatment option for the treatment of metastatic anaplastic lymphoma kinase gene rearrangement-positive NSCLC due to improved progression-free survival when compared to crizotinib. The development of skin toxicity can lead to early discontinuation of alectinib treatment, forcing providers and patients to select alternative, potentially less effective options. This case report provides evidence that patients who have experienced severe skin toxicity due to alectinib may be able to continue this first-line treatment option by rechallenging them using a desensitization procedure.

Sign in / Sign up

Export Citation Format

Share Document